Bebtelovimab
Based on 1 publication(s) in Google Scholar
Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy.
For research use only. We do not sell to patients.
- Purity : 97.41%
- CAS No.: 2578319-11-4
- Molecular Weight:143.82 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bebtelovimab
More
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
SARS-CoV-2
In Vitro
Bebtelovimab (1 h) effectively neutralizes authentic SARS-CoV-2/MT020880.1 virus with IC50 values ranging from 9-22.1 ng/mL[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
YP_009724390.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda2
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2578319-11-4
-
Appearance Liquid
-
Molecular Weight 143.82 kDa
-
Color Colorless to light yellow
-
SMILES
[Bebtelovimab]
-
Synonyms
LY-3853113; LY-COV1404
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Purity & Documentation
-
Data Sheet (258 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106(10):e463-e464. [Content Brief]
[2]. Bebtelovimab. IMGT/mAb-DB.
[3]. Westendorf K, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. bioRxiv [Preprint]. 2022 Mar 24:2021.04.30.442182. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bebtelovimab Related Classifications
HY-P99103 Related Classifications
Powered by Bioz